China launches tsunami advisory centre for disputed South China Sea
AP A Chinese navy ship, right, and a Chinese vessel is seen during a Philippine maritime patrol in the disputed South China Sea on Friday June 6, 2025.
China on Sunday launched the South China Sea Tsunami Advisory Centre and also a deep-sea test site to support fundamental deep-sea scientific research, technological innovation and the development of related industries.
The two launches coincided with the World Ocean Day that is celebrated on June 8 every year.
China, which claims most of the South China Sea, is locked in an intractable maritime dispute with the Philippines, Vietnam, Malaysia, Brunei and Taiwan, which have counter claims over the area that is home for busy regional and international trade routes.
The Tsunami Centre, which is based in Sanya in south China's Hainan province, started its operations aiming to provide marine disaster early warning services for regional countries, state-run Xinhua news agency reported. The facility, which was established by China's National Marine Environmental Forecasting Centre, and the Hainan provincial oceanic administration, seeks to develop a comprehensive multi-hazard early warning system for tsunamis, marine heatwaves, harmful algal blooms and other hazards, the report said.
It also aims to serve as a platform for international cooperation in marine forecasting and warning. The South China Sea region is prone to tsunamis and other marine hazards due to its complex tectonic setting, including active fault lines and frequent undersea earthquakes in nearby areas.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
18 hours ago
- News18
Scientists Warn Of Space Jam As Satellite Numbers Hit Critical Levels
Last Updated: As of May 2025, Earth is being circled by over 11,700 active satellites, a number that's climbing with astonishing speed SpaceX's Starlink accounts for 60% of active satellites. (News18 Hindi) Look up at the night sky and there's a good chance you're staring at more than just stars. As of May 2025, Earth is being circled by over 11,700 active satellites, a number that's climbing with astonishing speed. Data cited by Live Science revealed that more than 2,800 satellites were launched in 2024 alone, amounting to roughly one new launch every 34 hours. Much of this orbital rush is being driven not by governments, but by private space giants, with Elon Musk's SpaceX leading the charge. The company's ambitious Starlink program has already deployed more than 7,400 satellites, accounting for nearly 60% of all operational satellites currently in orbit. The surge is largely fueled by the rise of 'mega constellations", vast networks of satellites designed to deliver global internet and communication services, particularly in remote and underserved regions. Besides Starlink, other major contenders in the orbital broadband race include Amazon's Project Kuiper, the UK-based OneWeb, and a number of fast-expanding Chinese ventures. But while these projects promise to bridge digital divides, they're also triggering serious concerns about space sustainability. The region most affected is low-Earth orbit (LEO), the atmospheric layer extending up to 2,000 kilometres above the Earth's surface. Scientists warn that LEO has a 'carrying capacity", a threshold beyond which safe satellite operations become increasingly difficult due to congestion and the risk of collisions. That number is estimated at around 1,00,000 active satellites. At the current rate of launches, experts caution we may hit that ceiling well before 2050. Astronomer Jonathan McDowell of the Harvard-Smithsonian Centre for Astrophysics estimates the total satellite population, including inactive or defunct units, has already reached approximately 14,900. And as more commercial players enter the space race, that number is expected to explode. The implications are far-reaching. Beyond the immediate risks of in-orbit collisions and space debris, there are growing concerns over radio interference, light pollution affecting astronomical observations, and questions around regulatory oversight. First Published: June 10, 2025, 20:12 IST
Hindustan Times
19 hours ago
- Hindustan Times
Engineering humanity & where to draw a line
The future of human reproduction and genetic design is accelerating faster than most people understand, driven not by national debates or international accords, but by software startups, biotech investors, and quiet breakthroughs in fertility clinics. Nucleus Genomics recently unveiled Nucleus Embryo, a genetic screening platform that allows prospective parents to assess up to 20 embryos for more than 900 conditions and traits. These include not only polygenic risk scores for diseases such as cancer and Alzheimer's but also traits such as intelligence, height, and anxiety. In short, it offers a pathway to genetic optimisation — allowing parents to select not only healthier babies but the human features they want. Orchid, another US startup, pioneered full-genome sequencing of IVF embryos for disease screening. Once exclusive to the ultra-wealthy, Orchid's services are rapidly becoming more affordable, pointing to a future where embryo selection could become a standard step in family planning for both the middle and upper class. Meanwhile, Coinbase CEO Brian Armstrong, known for backing radical biotech ventures, has announced plans to launch a US company that would go beyond selection into embryo editing. Thanks to recent advances in base editing, it is now possible to alter individual DNA letters with high precision rewriting, rather than merely reading the code of life. The commercial race toward Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) babies has begun — and this is something I have long been both excited and terrified about. In a 2017 Washington Post article, I asked: 'Human editing has just become possible. Are we ready for the consequences?' I warned that CRISPR had made embryo editing technically feasible, but that society wasn't prepared for the moral fallout. I feared we would drift from preventing disease to designing our children. We have crossed this Rubicon. While the global community debates ethics and oversight, China is racing ahead with few restraints. Chinese scientists are editing the genes of animals — and even human embryos — not only to treat disease but to enhance traits such as intelligence and strength. Their goal appears to be the creation of so-called superhumans. Without international standards and ethical guardrails, unchecked ambition in any one country can pose risks for all of humanity. India must pay close attention. It has already misused reproductive technology: Ultrasound machines meant for foetal health monitoring were widely repurposed for sex selection. In Haryana, the sex ratio at birth has declined to 910 girls for every 1,000 boys. In a society shaped by caste, colourism, and academic pressure, gene editing could easily be co-opted to entrench inequality under the banner of 'better futures'. But more than vigilance, India must lead. With a deep-rooted traditions of spiritualism, karma and ethics, and respect for human dignity, it is uniquely positioned to offer the moral leadership this moment demands. Its scientific community is world-class, and its track record — from generic medicine to vaccine equity — shows it can pair innovation with compassion. The concerns extend far beyond reproduction. Gene-edited crops could marginalise small farmers if patented seeds are controlled by large corporations. CRISPR-based therapies, already costing more than $500,000 in the West, could deepen biological inequality. Even gene drives, designed to eliminate diseases such as malaria, could threaten delicate ecosystems like the Sundarbans if not deployed with care. To lead responsibly, India must act on four fronts. First, accelerate research. Universities and public institutions should partner with socially responsible entrepreneurs to build local expertise in gene editing, synthetic biology, and bioethics. This collaboration can ensure innovation is aligned with the public interest and rooted in Indian values rather than imported priorities. Second, access must be equitable. India has done this before with lifesaving generic drugs and can do this again. Public funding and subsidies must ensure CRISPR therapies reach rural and tribal populations suffering from genetic disorders like thalassemia. Third, the entire regulatory framework needs to be updated because existing biotech laws predate CRISPR. A new structure, co-created with scientists, ethicists, civil society, and patients, must define what is allowed, what is off-limits, and how oversight will function. Real engagement with the public, not just top-down mandates, will be essential. Fourth, India must lead globally. As it did in championing affordable vaccines, it can help shape international norms for genetic science, banning non-medical trait selection, regulating gene drives, and insisting on transparency and accountability. India can set the ethical benchmark, not merely follow it. We now have a rare opportunity to prove that scientific progress and moral clarity can coexist, but the window is narrow. We cannot rely on Silicon Valley, where profit is the only true metric of success, nor on China, where State control and repression define scientific ambition. Both paths risk taking humanity into dangerous territory. The world needs a third way, rooted in spiritual values, ethical reasoning, and the belief that technology must serve the many, not just the powerful, and this is the role India must play. Vivek Wadhwa is CEO, Vionix Biosciences. The views expressed are personal.
Mint
a day ago
- Mint
Chinese Firm Halts Production of Controversial Alzheimer's Drug
(Bloomberg) -- A Chinese company that developed the country's first indigenous therapy for Alzheimer's disease has suspended production and sales of the drug, casting doubts on the treatment's future. The drug's license has expired and its renewal is now in the final stages of a regulatory review, during which it must stop commercial production and sales, Green Valley Pharmaceutical Co. said in an emailed statement to Bloomberg News on Tuesday. The Shanghai-based drugmaker informed employees of the production halt in an internal notice at the end of May, local media Yicai reported first on Monday. Green Valley's drug — a seaweed-derived compound known as sodium oligomannate, or GV-971 — was hailed as a major advance when China's drug regulator gave it conditional approval in 2019, as the first new therapy endorsed for Alzheimer's in 17 years. Local and international medical experts have since questioned how effective it really is in slowing or reversing the cognitive declines of Alzheimer's patients given the relatively short duration of — and the inconsistent results shown in — its late-stage clinical trial in China. The company launched a global clinical trial in 2020, seeking to enroll some 2,000 patients across China, the US and Europe. It was terminated two years later due to a lack of funding and Covid pandemic disruptions. Green Valley previously conducted post-marketing clinical studies on around 3,300 patients on sodium oligomannate in China and has planned to present the results at an international academic conference later this year, according to the company. The changes are temporary and limited to operations related to sodium oligomannate, the company said, adding that drug supply for clinical trials is unaffected. 'We are in close communications with relevant authorities and believe patients' treatment needs will be met soon,' it said in the email. The closely-held company has not disclosed sales revenue for GV-971 in China, where it was included for national insurance reimbursement in 2022 at a price of around $41 per box. Hospital and retail sales of GV-971 topped $45.4 million (326 million yuan) that year, Yicai reported, citing figures from Pharnexcloud — a database of national hospital sales in China. China has since approved two new Alzheimer's therapies developed by multinational drugmakers: Biogen Inc. and Eisai Co.'s Leqembi, and Kisunla from Eli Lilly & Co. The country has 17 million dementia patients — about 30% of the global total — per a 2024 report led by Shanghai Jiao Tong University School of Medicine. More stories like this are available on
